FMP

FMP

Enter

BNOX - Bionomics Limited

Profile of Bionomics Limited(BNOX), Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug can

About

ceo

Dr. Spyridon Papapetropoulos M.D., Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.bionomics.com.au

exchange

NASDAQ

Description

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.

CIK

0001191070

ISIN

US09063M2052

CUSIP

09063M205

Address

200 Greenhill Road

Phone

61 8 8354 6100

Country

AU

Employee

8

IPO Date

Dec 16, 2021

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep